News Novo taps Anthropic's Claude AI for drug discovery Novo adds Anthropic AI models and Claude Science to its drug discovery toolkit in a bid to become "the world's most AI-driven healthcare company."
News Claude Science outperforms experts in protein binder task Using Claude Science, Claude agents designed high-affinity protein binders for a range of targets, outperforming human experts in some cases.
News argenx's Forte acquisition delivers coeliac trial win argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.